Insights - Merck announced data for their Phase 3 cough program this morning and it was rather disappointing. Cough effect in Phase 3 saw a large decrease from Phase … Continue Reading
Read nowInsights - Aerpio (ARPO) is developing a novel treatment for glaucoma that has Phase 2 data by the end of 2020. The company’s drug, razuprotafib, has shown to … Continue Reading
PremiumInsights - Affimed (AFMD) announced Q2 results today, which showed that the pipeline is progressing as planned. Below is an update for each candidate: AFM13: On Track … Continue Reading
Read nowInsights - Fennec announced that the FDA issued a CRL for Pedmark, citing manufacturing issues. The FDA did not identify any clinical safety or efficacy issues, so … Continue Reading
PremiumInsights - Today La Jolla (LJPC) announced Q2 results for Giapreza and numbers were very underwhelming. For the three months ended June 30, 2020, U.S. sales of Giapreza were $5.8 … Continue Reading
PremiumInsights - Fennec filed a trademark for their “PEDMARK” drug today. This is a good sign as Fennec is preparing for commercialization (and therefore FDA approval) of Pedmark. Fennec’s … Continue Reading
PremiumInsights - Essa (EPIX) announced an offering after market today. Although details on amount and pricing have not yet been disclosed, we think there will be strong … Continue Reading
Premium
